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Abstract
Drug lag, also known as drug innovation lag, can be categorized into marketing lag and reimbursement lag. This study investigates the trend and factors influencing drug innovation lag in Taiwan, and makes a comparison with major countries like USA,
Canada, Japan, and Europe on marketing lag. The reimbursement lag in the National Health Insurance (NHI) of Taiwan is also
explored. This is a retrospective study covering a total of 347 new drugs that were reimbursed by the Bureau of National Health
Insurance (BNHI) from 1996 to 2002. Data collection includes time of regulatory approval, type of innovation, country of origin,
and time and price of reimbursement by BNHI. The time of new drug approvals in study countries was obtained from relevant
websites for comparison. The drug lag index between Taiwan and study countries was also analyzed. Data were analyzed by SPSS
software for frequency distribution and multiple regressions. We found that new drugs are predominantly imported, and predominantly imported, and the average marketing lag was up to 30.5 months in Taiwan. Most of the new drugs were of me-too nature; only
very few could be classified as breakthrough new drugs. In terms of marketing lag, USA was the shortest (5.6 months), followed
by European countries (8.2 months), Canada (18.0 months), and Taiwan (30.5 months). The reimbursement lag was 11.7 months
on average after product license granted by DOH, yet it was not affected by the NHI reimbursement price. The drug lag index from
smallest to largest was: the USA (0.14), Europe (0.21), Canada (0.45), and Taiwan (0.76). Drug marketing lag is a serious issue in
Taiwan. The average marketing lag of 30.5 months could be attributed to the fact that nearly all new drugs were of foreign origins.
The average time after DOH’s regulatory approval to NHI reimbursement was as long as 11.7 months. The government should reexamine the current function of the regulatory and reimbursement systems. More specifically, the health authorities should focus on
faster regulatory process for breakthrough medicines instead of approving only “me-too new drugs”.
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Introduction
The regulatory approval time for new drugs is a recurring focus for healthcare policy analysts in many countries.
New drug applications have been evolved into a complicated and time-consuming regulatory process since the
thalidomide event in the early 1960s. It was intended to
ensure drug safety and efficacy, but may compromise public
accessibility to pharmaceutical innovation in time. The delicate balance between drug safety and drug accessibility has
become an important policy issue.
Drug innovation lag is mostly related to the regulatory
process of new drug approvals. It refers to the phenomenon
whereby the introduction of new drugs into a country is
delayed, and the inefficiency of the regulatory system was
regarded as the cause of the delay(1). In countries that have
national health insurance systems, drug reimbursement lag
or social drug lag is caused by the delayed listing of new
drugs into benefit coverage. In the United States, Medicaid
patients may not have access to newly approved drugs
because of formulary restriction by state governments. In
countries like Australia, Canada and France, the third party
payment system requires cost-benefit evaluation before a
new drug can be reimbursed(2-5). Schweitzer developed the
drug lag index, or the Drug Availability Index (DAI), as the
measuring stick of drug lag. DAI measures the time taken
* Author for correspondence. Tel: +886-2-2826-7175;
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for the new drug to be approved in a certain country within
four years of its approval in the first country. DAI ranges
from 0 (no drug lag) to 1 (serious drug lag), a larger value
indicating a more serious drug lag(2). Andersson, however,
further classified drug delay into relative drug lag (the relatively early introduction of new drugs in some countries
compared to other countries) and absolute drug lag (i.e.,
some drugs are never introduced into a country)(6).
Studies on drug lag mostly focused on industrialized countries, especially the United States and European
countries. Wardell compared the introduction of new drugs
in the UK and the USA during 1962-1971 with focus on
nine types of therapy. Each country had an average of 2.4
years and 2.8 years of drug lags against the other country
respectively. In terms of relative drug lag, 82 new drugs
were introduced in the UK 0.7 years earlier than in the USA
while the absolute drug lag indicated that 77 new drugs introduced in the UK were never introduced in the USA and
21 new drugs were introduced only into the USA during the
study period(7).
Since Wardell’s publication in 1973, numerous researches involving international comparative studies were
published and focusing on relative drug lag and absolute
drug lag. There were substantial differences between the
numbers of new chemical entities (NCEs) introduced to
studied countries. In addition, most new drugs were also the
first introduced into their country of origin(8-12). Rawson
examined the new drug approval time between 1999~2001
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in USA, UK, Sweden, Australia and Canada, and found that
USA had the shortest process time of 371 working days, followed by Sweden, UK and Australia, while Canada had the
longest process time(13-14).
The only one study on new drug approval process
in Taiwan in 1992 involved 182 new drugs introduced
between 1989 and 1991 (15). It took an average of 34.2
months for a new drug to be approved in Taiwan from the
date it was marketed in its originating country, while it
took drug manufacturers an average of 13 months from
submitting an NDA to obtaining drug approval by the Department of Health (DOH).
This study explored the factors affecting drug innovational lag in Taiwan, and compared such trend with
that of major countries (USA, Canada, European Union
and Japan). The reimbursement lag by the Bureau of
National Health Insurance (BNHI) after license approval
was also explored.

Methods
I. Measurement
The drug lag in this study was based on medicines
introduced to Taiwan, USA, the EU and Canada during
1996~2002. It was defined by the difference between the
time a drug received its first license in the study countries
and the time it was approved for marketing in Taiwan. The
reimbursement lag is the time lag between drug approval by
the DOH and its reimbursement by the BNHI.
The therapeutic groups are based on the Anatomical
Therapeutic Chemical (ATC) classification system of the
WHO Collaborating Centre for Drug Statistics Methodology. By ATC, drugs are classified into 13 groups including
those pertaining to the alimentary tract and metabolism (A),
the blood and blood-forming organs (B), the cardiovascular
system (C), and rare diseases (X), etc.
The classification of new drug innovation is based on
three categories proposed by the the Canadian Patented
Medicine Prices Review Board (PMPRB): category 1 (line
extension) comprises new drugs with a similar chemical
composition to existing drugs but differing in method of administration; category 2 (breakthrough) describes new drugs
which provide the first effective treatment of a particular disease; and category 3 (me too) comprises new drugs or new
dosage forms of existing drugs that have similar therapeutic
effect to existing drugs (http://www.pmprb-cepmb.gc.ca).
II. Data Collection and Analysis
This study reviewed 347 new drugs listed for
reimbursement by the NHI between 1996 and 2002. The
approval time of new drugs in various countries were obtained from the websites of the following entities: CDER
in FDA (USA), Health Products and Food Branch, Department of Health (Canada), the European Agency for the

Evaluation of Medicinal Products (EMEA); Japan Pharmaceutical Manufacturers Association (Japan), and the
Bureau of Pharmaceutical Affairs, DOH (Taiwan). In addition, the drug innovation level was based mainly on the
Canadian PMPRB, while the data on the country of origin
were obtained from Taiwan’s DOH. The reimbursement
time and the approved price were obtained from the BNHI
website.
Data were analyzed using the SPSS software for frequency distribution and multi-regression.

Results
15.3% of the 347 new drugs covered in this study
were from Taiwan and the remaining 84.7% were from
foreign countries. Taiwan ranked the number one country
of origin (15.3%), followed by UK, USA, Germany and
France in descending orders. In terms of ATC grouping,
the leading five categories are drugs for nervous system (N)
15.3%, drugs for systemic anti-infective use (J) 14.7%, antineoplastic/immunomodulating agents (L) 13.8%, agents for
respiratory system (R) 10.1%, and agents for cardiovascular
system (C) 8.4%. Drugs for rare diseases (1.2%), systemic
hormonal preparations (1.4%), and genito urinary system
and sex hormones (4.0%) are a minority.
Since the data on new drug innovation attributes are
based on the Canadian PMPRB classification, only 124
new drugs (36%) were available for analysis. Category
1 (me too new drug) accounts for the largest proportion
(70.2%) while drugs of significant breakthrough make up
only 11.3% (Table 1). Regarding reimbursement price in
NHI, we observed a negative skew distribution whereby
62.0% were priced below NT$ 200. Nevertheless, distribution became normal when corrected with natural logistic
transformation (Ln).
For the 80 new drugs that were all approved for
marketing in the study countries, the average drug lag
in Taiwan was 30.5 months when compared to the first
approval in other countries. Bivariate analysis indicated
that there was no difference in terms of domestic/foreign
origins (P = 0.355), yet there were statistically significant
differences in terms of country of origin (P = 0.024), ATC
therapeutic group (P = 0.004), and new drug innovation attribute (P = 0.018).
The average lag between DOH’s approval and the
listing of NHI reimbursement was 11.7 months. Only the
ATC therapeutic group (P = 0.001) showed a significant
difference in the bivariate analysis. The other factors, such
as domestic/foreign origin, country of origin, innovational
attributes of new drugs, and ln (drug prices expressed in log
value) all showed no significant difference.
I. Multiple Regression Analysis
While predicting the regression model of marketing
lag, the variable of drug innovation attributes was excluded
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due to limited data availability. There was also a problem
of co-linearity in the analysis when domestic/foreign origin
was taken into account. Therefore, only two variables
(country of origin and ATC category) were included in the
multiple regression analysis. Since most variables were
categorical, virtual variables were created for further analysis and grouped to facilitate the application of the multiple
regression model. Genito-urinary system and sex hormones
(G) and rare disease drugs (X) were excluded from the

model as the frequency of these categories was zero. The
remaining categories with less than 5% frequency were
combined as a single group. In total, only 8 groups and
7 virtual variables were analyzed. Country of origin was
grouped into five categories: (1) Taiwan, (2) USA and Canada, (3) European countries (UK, Germany, France, Belgium, Sweden and Switzerland), (4) Asian countries (Japan
and Australia), and (5) other countries (Italy, Puerto Rico,
Spain, Denmark and Finland).

Table 1. Description of NHI reimbursed new drugs in Taiwan (1996~2002)
Characteristics

Number of new drugs listed (%)

Country of origin (n = 347)
Taiwan

53 (15.3)

UK

44 (12.7)

USA

33 (9.5)

Germany

29 (8.4)

France

28 (8.1)

Others (Japan, Switzerland, Puerto Rico, Australia, Sweden, etc)

160 (46.1)

ATC therapeutic group (n = 347)
Agents for nervous system (N)

53 (15.3)

Anti-infective for systemic use (J)

51 (14.7)

Anti-neoplastic and immunomodulating agents (L)

48 (13.8)

Agents for respiratory system (R)

35 (10.1)

Agents for cardiovascular system (C)

29 (8.4)

Others

131 (37.8)

New drug attribute (n = 124)
Line extension new drug (category 1)

23 (18.5)

Breakthrough new drug (category 2)
Me too new drug (category 3)

14 (11.3)
87 (70.2)

Table 2. Multiple linear regression analysis of drug lag (n = 80)
Variables

T value

P value

-14.471

-2.511

0.014a

Musculo-skeletal system (M)

-4.332

-0.688

0.494

Respiratory system (R)

-6.781

-1.032

0.306

Cardiovascular system (C)

-2.816

-0.420

0.676

-21.198

-2.695

0.009b

-7.183

-0.909

0.367

-16.152

-2.629

0.011a

ATC therapeutic group
Nervous system (N)
Anti-neoplastic and immunomodulating agents (L)

Anti-infective for systemic use (J)
Sensory organs (S)
Others (A, B, D, H)c

Regression coefficient
Reference

Country of origin
Taiwan

Reference

USA, Canada

-42.936

-4.012

0.000b

UK, Germany, France, Belgium, Sweden, Switzerland

-35.747

-3.597

0.001b

Japan, Australia

-37.651

-3.015

0.004b

-32.865
73.168

-3.260

0.002b

Others
Constant
AdjR2 = 0.237; F = 3.232b
a

p < 0.05.
p < 0.01.
c
Alimentary tract and metabolism (A); blood and blood forming organs (B); dermatologicals (D); systemic hormonal preparations (H).
b
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Table 3. Multiple linear regression analysis of reimbursement lag (n = 280)
Variables

Regression coefficient

T value

Reference
2.214

1.045

0.297

Anti-infective for systemic use (J)

5.808

2.888

0.004a

Respiratory system (R)
Cardiovascular system (C)

1.368
0.731

0.632
0.294

0.528
0.769

Sensory organs (S)

6.606

2.740

0.007a

ATC therapeutic group
Anti-neoplastic and immunomodulating agents (L)
Nervous system (N)

Blood and blood-forming organs (B)

P value

0.658

0.270

0.787

-3.521

-1.293

0.197

Dermatologicals (D)

1.858

0.694

0.488

Alimentary tract and metabolism (A)

0.994

0.355

0.723

Others (G, H, X)c

2.106

0.848

0.397

Musculo-skeletal system (M)

Country of origin
Taiwan

Reference

USA, Canada

3.747

1.709

0.089

UK, Germany, France, Belgium, Sweden, Swiss

1.479

0.866

0.387

Japan, Australia

0.437

0.200

0.841

Others

1.759

0.973

0.332

0.106
7.751

0.348

0.728

Lnd (drug price)
Constant
AdjR2 = 0.098; F = 1.902a
a

p < 0.05.
p < 0.01.
c
Genito-urinary system and sex hormones (G); systemic hormonal preparations (H); rare diseases (X).
d
Log value.
b

In Table 2, the regression model shows a significant
difference in the marketing lag (F = 3.232, P = 0.001) with
an explainable proportion coefficient, R2 = 0.237. For individual ATC group and country of origin, the p values of antineoplastic and immunomodulating agents (L), anti-infective
for systemic use (J), and others (including A, B, D, H) and
source of origin (categories 2, 3, 4, and 5) showed a statistically significant difference to the control group.
When calculating the reimbursement lag, a drug
Fluarix was excluded as if it is distributed without a
value. The variables of drug innovation type and country
of origin were also excluded with the former excluded
due to limited data availability and the latter due to the
problem of co-linearity. All the remaining variables (ATC
category, country of origin, and NHI reimbursement price)
were taken into the multiple regression model analysis.
In the ATC category, the categories with less than 5%
representation were grouped together, including genitorurinary system and sex hormones (G), systemic hormonal
preparations (H), rare diseases (X). There were a total of
10 groups of which 9 virtual variables were set for the regression analysis together with source of origin and NHI
reimbursement price.
As shown in Table 3, the result of the regression
model presented a statistically significant difference (F =
1.902, P = 0.023) with the regression coefficient value of
R 2 = 0.046, whereas only the individual coefficients of

anti-infective for systemic use (J) and sensory organs (S)
showed a statistical difference.
II. Comparison between Countries
Only 4 drugs were available simultaneously in Taiwan,
Japan, USA, the EU, and Canada. However, excluding Japan
from analysis, 80 new drugs were available simultaneously
in the remaining four countries. Among 80 new drugs, USA
has the shortest marketing lag of 5.6 months, followed by
the EU (8.2 months), Canada (18.0 months), and Taiwan
(30.5 months). The indexes of drug lag were 0.14 for the
USA, 0.45 for Canada, 0.21 for EU, and 0.76 for Taiwan,
indicating that the drug lag in Taiwan was the most serious.

Discussion
The introduction of innovational new drugs in Taiwan
has been heavily dependent upon the importing sources,
especially UK, USA, Germany, France, and Japan. This
phenomenon is expected since these countries belong to
pharmaceutically developed countries. 5.7% of new drugs
were imported from Puerto Rico, attributable to the tax
incentives that attract American pharmaceutical companies
to invest. Although 53 new drugs were of domestic origin,
25 (47.2%) were actually produced by member companies
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of the International Research-Based Pharmaceutical Manufacturers Association (IRPMA) and 28 (52.8%) by nonmembers. Non-member companies TTY Biopharm, Yung
Shin Pharm and Ko Chin Pharm accounted for 13 new
drugs.
Leading ATC categories of new drugs are for treatment of the nervous system, systemic anti-infective,
tumors, respiratory system, and cardiovascular system.
This closely mirrors the current emphasis on drug research and development.
Regarding the attribute of innovation that was based
on Canadian PMPRB criteria, 70.2% (72/124) of new
drugs introduced to Taiwan are of me-too nature, 11.3% are
breakthrough new drugs. Contrary to the findings of the
OECD report(16). The ‘me too’ new drugs are favored by
pharmaceutical companies as they offer similar therapeutic
effects as innovative drugs but are relatively risk free from
the regulatory perspective. It, however, may significantly
increase overall medical expenditure. It is worth noting that
the criteria of Canada’s PMPRB on new drugs categorization
take both financial perspective in health insurance and their
therapeutic value into consideration. Therefore, PMPRB
has stricter definition of innovative drugs. In addition,
new drugs not available in both Canada and Taiwan are not
included for this analysis, therefore, the interpretation of this
result should be taken conservatively.
The marketing lag in Taiwan is 30.5 months in this
study, 3.7 months shorter than the 34.2 months reported
by Cheng in 1992(15). Although the definition of these
two studies are not the same, Cheng defined the time lag
based on the approval time of the originating country while
this study adopted the first approval time among the study
countries. It can still project a trend that the marketing lag
in Taiwan has not been improved. It could also be caused by
delay in an NDA submission by the pharmaceutical company. In order to promote the development of pharmaceuticals
industry in recent years, it is important for the government to
create a more favorable regulatory environment to expedite
the approval time for new drugs.
In the regression analysis after controlling the ATC
groups, USA and Canada have a negative coefficient of
42.936, indicating that these countries have a decreasing
effect on the marketing lag in Taiwan. In other words,
marketing approvals in both USA and Canada are much
sooner than that of Taiwan. The European and Asian countries come next with coefficient of -35.747 and -37.651,
respectively, both moving toward a decrease in marketing
lag. These findings are consistent with the observation that
a country enjoying a more substantial market would be more
aggressive to launch their products in Taiwan, which in turn
narrow the marketing lag in Taiwan.
When the country of origin is used as a control, the
ATC groups of anti-tumor and immune system regulation
(L), systemic anti-infective (J) and others all show significant negative coefficients. This means new drugs in these
therapeutic groups are introduced into the Taiwanese market
earlier than new drugs for nervous system of the control

Reimbursement lag
Marketing lag

1

2

3

4

Figure 1. Drug innovational lag (marketing lag and reimbursement
lag). 1. The new drug approved in the first country; 2. NDA
submission for license approval in Taiwan; 3. NDA approved by
Taiwan; 4. New drug listed in NHI for reimbursement.

group. As a result, patients suffering from cancers have
better access to these new drugs.
The main purpose of comparing drug lag index is
to gradually decrease drug lag as regulatory experiences
among various countries were accumulated. USA has the
smallest drug lag index (0.14), followed by the EU (0.21),
Canada (0.45) and Taiwan (0.76). This figure indicates
drug lag index in Taiwan is 5.43 folds, 3.62 folds and 1.69
folds of USA, EU and Canada, respectively. Since USA is
the leading country in the world for new drug research and
development, it makes sense that USA has the smallest drug
lag index. Great drug lag index in Taiwan is understandable
since nearly all new drugs are of foreign origins.
In fact, marketing lag may happen as a result of two
time periods: an NDA submission time by a pharmaceutical
company and license approval time by the health authority.
Delayed NDA submission will automatically create
marketing lag, while inefficient regulatory process will
also contribute to the marketing lag. Our study did not
differentiate the marketing lag based on the above two time
factors because the submission time for an NDA was not
available for analysis.
When country of origin and the NHI reimbursement
price are maintained as control, the ATC groups of systemic anti-infective (J) and drugs for sensory system (S)
show significant difference but only with small positive
values, meaning NHI reimbursement is more difficult for
these therapeutic groups than for the control group (antitumor and immune system regulation (L). Although drugs
for systemic anti-infective (J) have a negative correlation
coefficient in marketing lag, the regression coefficient of its
reimbursement lag is positive. It could be interpreted that
there may be a reimbursement lag without presence of the
marketing lag.
When other variables are held constant, NHI
reimbursement price does not have a notable effect on the
reimbursement lag in Taiwan. This is a good sign. This
research started with the hypothesis that drug pricing affects
reimbursement lag, as this lag might be prolonged considerably for expensive new drugs which in term will affects
public access to new drugs. However, our findings showed
that such consideration does not exist in Taiwan.


Journal of Food and Drug Analysis, Vol. 14, No. 1, 2006

This study also found that for the new drugs approved
prior to 1996 yet were reimbursed only after NHI
implementation, the average reimbursement lag was 13.3
months, not much different from those new drugs approved
after 1996. Therefore, no further analysis was performed.
Due to the co-linearity on domestic/foreign source
with country of origin and data availability on innovation
attributes, the reimbursement lag was not significant after
controlling other variables. It is good to see that there is
no effect of new drug price on reimbursement lag. It was
hypothesized that reimbursement lag may exist for more
expensive new drugs which in turn will affect public access
to pharmaceutical innovations. This study provides an
evidence-based result to dissolve such concern. The BNHI
may not be responsible for the average reimbursement lag of
11.7 months because that the new drug license holders are
not required by law to apply for NHI listing and pricing after
license approvals. It may take the license holder several
months after license approval to submit NHI reimbursement
application.
Since countries vary on the regulatory process of
NDAs, data were collected primarily based on drug brands
and supplemented by manufacturers in order to maximize
sample size. Moreover, this study based on the new drugs
listed for NHI reimbursement during 1996~2002 which may
not be 100% consistent with the new drugs approved by the
DOH during this study period.

Conclusions
Drug lag, especially marketing lag, is a serious issue
in Taiwan. The average marketing lag in Taiwan is 30.5
months since its first approval in other country. The drug
lag index of 0.76 also far exceeds corresponding figures
of USA (0.14), EU (0.21), and Canada (0.45). We found
no reimbursement lag for NHI listed new drugs during
1996~2002 due to NHI reimbursement prices. However,
the average time lag after regulatory approval to NHI reimbursement is as long as 11.7 months. We recommend
the government to examine the current regulatory and reimbursement process for new drugs. Focus should be on
encouraging faster market access to breakthrough medicines
instead of devoting substantial efforts to approve “me-too
new drugs”.
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